Gynecology Drugs Global Market Report 2025

Gynecology drugs pertain to the medical field specializing in the treatment of illnesses affecting the female reproductive system, encompassing care for women during pregnancy and childbirth. These drugs serve the purpose of treating various gynecological diseases that may impact the uterus, ovaries, and appendages.

The primary therapeutic categories within gynecology drugs include hormonal therapy and non-hormonal therapy. Hormonal therapy involves treatments that either add, block, or remove hormones to impede the growth of cancer cells reliant on hormones for their development. Non-hormonal therapy includes the use of anti-infective and anti-inflammatory agents, lubricants, moisturizers, as well as medications such as antidepressants, gabapentin, clonidine, among others. Gynecology drugs find application in treating conditions such as gynecological cancers, menopausal disorders, polycystic ovary syndrome, contraception, and more. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The gynecology drugs market research report is one of a series of new reports from The Business Research Company that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecology drugs market size has grown strongly in recent years. It will grow from $43.27 billion in 2024 to $45.52 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to a rise in the introduction of drugs with novel mechanisms, a rise in educational tools and awareness on menopause, a rise in long-acting reversible contraceptives, a shift in lifestyles, a rise in healthcare awareness and expenditure, government initiatives and an increase in pharmaceutical R&D expenditure.

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to $57.08 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to an increase in awareness and use of contraceptives and hormone replacement therapy (HRT), an age-related increase in gynecological cancers, a rise in ovarian cancer, prevalence of gynecological diseases, a rise in healthcare expenditure and rising investment to understand the mechanisms of endometriosis and its treatment. Major trends in the forecast period include companies should consider launching or adopting new treatment developments to treat patients with oncology and endometriosis and give them a longer survival time, focus on the development of new menopausal hormone therapy to offer better treatment options, investments in gynecology drugs research that will create new opportunities to create and develop new drugs, increase awareness about benefits of contraceptives and launch new products into the market to fulfill the unmet need from developed and developing countries, develop antibody-drug conjugates (ADCs) targeted therapies to target ovarian cancers, consider entering into strategic collaborations and partnerships to broaden their product portfolios, boost revenues and establish category leadership and focus on combination therapies to overcome drug resistance and reduce morbidity and mortality caused due to traditional cancer treatments.

The anticipated increase in the number of women affected by ovarian cancer is expected to drive growth in the global gynecological drugs market. Ovarian cancer, originating in the ovaries as part of the female reproductive system, is effectively managed by gynecological drugs that offer targeted treatment options, improved survival rates, and enhanced quality of life for patients. According to estimates from Globocan, the global incidence of ovarian cancer is projected to reach 434,184 by 2040, thereby fostering the demand for gynecological drugs in the foreseeable future.

Age serves as a significant risk factor for various diseases, including diabetes, obesity, neurodegenerative disorders, and cancer. In particular, disruptions in female reproductive cycles, such as early menarche or late menopause, contribute to hormonal imbalances and increase the risk of cancer in later stages of life. Endometrial and ovarian cancers are prevalent among elderly women and contribute to substantial mortality rates. The incidence of these cancers rises with age, typically peaking around 60 to 70 years. Additionally, cervical cancer is commonly diagnosed around the age of 50, while vaginal and vulvar cancers are typically diagnosed later, around the age of 67. For instance, the American Cancer Society estimates 14,000 new cases of cervical cancer in the United States in 2022. The age-related upswing in gynecological cancers is expected to propel the market in the coming years.

Major companies in the gynecology drug market are focusing on the development of innovative medications, such as hormonal therapies, to address moderate to severe pain associated with endometriosis. Hormonal medications are drugs that contain hormones or hormone-like substances used to regulate or alter hormonal levels in the body for various conditions, including hormone replacement therapy, birth control, and endocrine disorders. For example, in August 2022, Myovant Sciences, a US-based biotechnology research company, and Pfizer, a US pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for managing moderate to severe pain linked to endometriosis. Endometriosis is a painful condition characterized by tissue similar to the uterine lining growing outside the uterus, affecting millions of women worldwide. The approval of MYFEMBREE marks a significant advancement in treatment options for this condition, offering a new oral medication that combines hormonal therapy with a GnRH antagonist. Overall, the direction of the gynecology drug market underscores a commitment to addressing the unique healthcare needs of women, ensuring they have access to the best available treatments.

Major companies in the gynecology drug market are focusing on developing innovative therapies, such as hormone replacement therapy (HRT), to gain a competitive advantage. HRT is a medical treatment that involves administering hormones to alleviate menopause symptoms, including hot flashes, night sweats, mood swings, and vaginal dryness, thereby enhancing the overall quality of life for women undergoing these changes. For example, in April 2023, the Department of Health and Social Care in the UK, in collaboration with NHS England and the NHS Business Services Authority, launched a new HRT prescription prepayment certificate (PPC). This initiative allows women in England to access HRT for only £19.30 per year (approximately $24.50 USD), significantly easing the financial burden of managing menopause symptoms.

In March 2022, Carlyle, a U.S.-based private equity firm, and PAI Partners, a France-based private equity firm, reached an agreement to acquire Theramex from CVC Capital Partners for $1.4 billion. This acquisition is intended to expand the investment portfolio of Carlyle and PAI in Theramex, focusing on organic, inorganic, and international growth initiatives. Theramex, a UK-based pharmaceutical company, specializes in women's health products related to fertility, contraception, menopause, and osteoporosis.

Major companies operating in the gynecology drugs market include Merck & Co. Inc., AbbVie, Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Ferring Holding SA, TherapeuticsMD Inc., Lupin Pharmaceuticals Inc., Johnson & Johnson, Eli Lilly and Company, Bayer AG, Abbott Laboratories Ltd., AstraZeneca, Amgen Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Allergan plc, Sanofi S.A., Coloplast A/S, Cipla Limited, Endo International PLC, Glenmark Pharmaceuticals Limited, S.K. Chemicals Co. Ltd., Dong A Pharmaceutical Co., Novartis AG, Furukawa Electric, Motherson Sumi, LS Cables & Systems, HUBER+SUHNER, Acome, Yazaki Corporation, Fujikura Ltd., Robert Bosch, HELLA GmbH & Co. KGaA, Coroplast Harness Technology Sp. z o.o.

North America was the largest region in the gynecology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gynecology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gynecology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gynecology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gynecology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Hormonal Therapy, Non-Hormonal Therapy
• 2) By Indication: Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, Other Indications
• 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• Subsegments:
• 1) By Hormonal Therapy: Estrogen Replacement Therapy; Progesterone Therapy; Combination Hormonal Therapy
• 2) By Non-Hormonal Therapy: Antidepressants (For menopausal symptoms); Non-Hormonal Anticonvulsants; Herbal And Dietary Supplements
• Companies Mentioned: Merck & Co. Inc.; AbbVie; Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.